https://www.selleckchem.com/pr....oducts/carfilzomib-p
We thank Drs. Jindal and Sarin for their correspondence regarding our study of the nonsteroidal FXR agonist cilofexor in NASH. The objective of this Phase 2a study was to obtain preliminary evidence regarding the safety, pharmacokinetics, pharmacodynamics, and efficacy of cilofexor, including dose response. Indeed, our observations informed the 48-week ATLAS trial of cilofexor as monotherapy and in combination with other compounds that includes histologic endpoints (NCT03449446). Although reductions in liver transaminases wer
Like
Comment
Share
